Clinical

A cardiovascular researcher explains why her team compared cardiac risks of COVID-19 infection and vaccination head-to-head.

Amandeep Godara, MBBS, discusses how patient factors, disease burden, and logistics guide treatment decisions in relapsed/refractory multiple myeloma.

Shiven B. Patel, MD, MBA, discussed strategies for overcoming tissue limits, delays, and rural access gaps in NSCLC biomarker testing at an IVBM event.

Selinexor, an oral XPO1 inhibitor, delivers modest spleen volume reduction in ruxolitinib-refractory MF with minimal myelosuppression in ESSENTIAL trial news.

A Chest study of 1576 patients finds a 20% emphysema threshold best predicts survival and lung function decline in fibrotic ILD.

New multi-center registry data confirm MAC as the dominant cause of NTM pulmonary disease, while culture conversion with standard therapy still fails in nearly half of patients.

Better risk stratification, more tolerable regimens, and outcome measures beyond culture conversion top the list of unmet needs Dr. Losier identifies for MAC and NTM pulmonary disease heading into ATS 2026.

Systematic review maps 410 lymphoma antibody drug conjugates clinical trials, revealing limited diversity beyond MMAE, few survival end points, and scarce biomarkers in DLBCL and classical Hodgkin lymphoma.

Hepatitis B elimination requires expanded vaccination, screening, treatment, and education, Helen Nde, MPH, said.

FDA approves rusfertide, a first-in-class hepcidin-mimetic for polycythemia vera, cutting phlebotomies and improving hematocrit control and QOL.

China survey reveals what R/R mantle cell lymphoma patients and doctors value after BTK failure—overall survival tops trade-offs despite CRS risk.

A 3-cohort study finds CC16 levels flag airway remodeling and fibrosis-like lung damage up to 3 years after severe COVID-19.

Almandoz challenged one of the most persistent misconceptions in metabolic disease management, that obesity treatment is primarily about weight loss, arguing instead that obesity is a systemic driver of healthcare utilization across multiple high-cost disease states including type 2 diabetes, cardiovascular disease, osteoarthritis, chronic kidney disease, and MASH, and that by the time a patient develops liver cirrhosis, heart failure, or end-stage kidney disease, the financial and human costs have already become enormous and largely preventable with earlier intervention.

Almandoz described his interpretation of the SYNCHRONIZE-1 findings, noting that while substantial and statistically significant weight reduction was observed, what captured his attention most was the nature and distribution of that weight loss, with the MRI sub-study demonstrating meaningful reductions in visceral and liver fat alongside relative preservation of lean mass, collectively pointing to a quality of weight loss that is biologically distinct from generalized weight loss.

A 4-million-person study finds unvaccinated COVID-19 infection raises myocarditis, pericarditis, and death risk far more than the Pfizer vaccine.

Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally defined high-risk patients.

County-level CRC mortality fell substantially since 2000, but some counties still had rates more than 13 times the Healthy People 2030 target in 2019.

Major depressive disorder (MDD) is a heterogeneous disorder with many unique symptom combinations.

Tara Graff outlined a practical framework for community oncology practices looking to establish safe and successful programs with novel regimens, emphasizing that while tafasitamab-based combinations can be adopted with relatively minimal operational changes, bispecific antibodies require more deliberate infrastructure investment, but that every community site has the capacity to build this capability with the right approach.

Hepatitis B and hepatitis C behave nothing alike once treatment succeeds. This episode explains why hepatitis B's genomic integration makes true virologic cure fundamentally more complex than hepatitis C clearance.

Tara Graff highlighted the significance of 2025 as a landmark year for RRFL treatment, with the June 2025 approval of tafasitamab plus R² and the November 2025 approval of epcoritamab plus R² representing two major additions to the NCCN guidelines that meaningfully expand the second-line treatment options available to follicular lymphoma patients beyond the R² backbone and signaling a clear directional shift toward novel, non-chemotherapy combinations that can deliver progression-free survival measured in years.

Welcome back to another AJMC Peer Exchange series. In this episode titled, "The Burden of Major Depressive Disorder: Setting the Stage for Managed Care."

Tara Graff discussed her experience with epcoritamab-based combinations in follicular lymphoma, noting that her practice's participation in both epcoritamab monotherapy and combination therapy trials has provided her with firsthand familiarity with the regimen and that the efficacy data, particularly the overall response and complete response rates associated with epcoritamab plus R², is compelling.

Guideline inconsistency and treatment thresholds continue to create gaps in chronic hepatitis B care, particularly in primary care settings. This episode also examines what functional cure means for cancer risk and long-term antiviral safety.